Possible antiproliferative action on tumor cells reported
Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly.
British Journal of Cancer (2006) 95, 197–203. doi:10.1038/sj.bjc.6603236 www.bjcancer.com
Published online 27 June 2006
A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
M Guzmán1, M J Duarte2, C Blázquez1, J Ravina2, M C Rosa2, I Galve-Roperh1, C Sánchez1, G Velasco1 and L González-Feria2
- 1Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid 28040, Spain
- 2Department of Neurosurgery, Hospital Universitario de Canarias, La Laguna, Tenerife 38320, Spain
Correspondence: Professor M Guzmán, E-mail: mgp@bbm1.ucm.es; Professor L González-Feria, E-mail: lgferia@yahoo.es